- Home
- Industries
Aerospace And Defence
Agriculture
Automotive And Transportation
Banking And Finance
Business
Chemicals And Materials
Consumer And Retail
Electronics And Semiconductors
Food And Beverages
Machinery & Equipments
Manufacturing And Construction
Medical Devices
Others
Pharmaceuticals And Healthcare
Power And Energy
Sports
Technology
- Services
- News Room
- About us
- Contact Us
-
Global Continuous Glucose Monitor Market Size, Share | CAGR 14.8%
Global Continuous Glucose Monitor Market Size, Share, Analysis By Component (Sensors, Transmitters, Receivers & Monitors), By Application (Type-1 Diabetes, Type-2 Diabetes Management, Gestational Diabetes, Critical Care Monitoring), By Demography (Adult Population, Pediatric Patients), By End-User (Homecare Settings & Personal Use, Hospitals & Clinics, Diagnostic Centers) Region & Key Players-Segment Overview, Dynamics, Strategies & Forecast 2026-2034
Report Overview
| Market Size (2025) | Forecast Value (2034) | CAGR (2026-2034) | Largest Region (2025) |
| USD 13.80 Billion | USD 47.74 Billion | 14.8% | North America, approximately 47.0% |
The Continuous Glucose Monitor Market was valued at USD 12.10 Billion in 2024 and USD 13.80 Billion in 2025. The market is projected to reach USD 47.74 Billion by 2034, expanding at a CAGR of 14.8% during the forecast period from 2026 to 2034. This represents an absolute dollar opportunity of USD 33.94 billion over the analysis period.
Continuous Glucose Monitor Market Global Forecast to 2034 (USD)
CAGR OF
14.8%
Continuous Glucose Monitor Market
Get more details on this report -
The 2025 market value is anchored to company-disclosed and investor-referenced estimates. Abbott's 2025 annual report identified the global continuous glucose monitoring market at approximately USD 14 billion, while Senseonics' November 2025 investor presentation referenced a USD 13.5 billion 2025 global CGM market. The adopted midpoint of USD 13.80 billion reflects a blended estimate across those disclosures.
Demand is driven by diabetes prevalence, insulin therapy, type 2 diabetes expansion, payer coverage, and over-the-counter CGM access. The International Diabetes Federation reported in 2025 that 11.1% of adults aged 20-79 live with diabetes, equal to roughly 1 in 9 adults, and projected 853 million adults with diabetes by 2050.
The market is shifting from prescription diabetes management to broader metabolic monitoring. The FDA cleared Dexcom Stelo in March 2024 as the first over-the-counter continuous glucose monitor for adults not using insulin, and Abbott received FDA clearance in June 2024 for Lingo and Libre Rio.
Competition is concentrated among Abbott Laboratories, Dexcom, Medtronic's diabetes business, and Senseonics. Abbott remains the revenue leader through FreeStyle Libre, Dexcom competes through G6, G7, Stelo, and G7 15-Day, Medtronic links CGM with MiniMed automated insulin delivery, and Senseonics differentiates through the long-duration Eversense 365 implantable CGM system.
Market Definition & Scope
The continuous glucose monitor market is defined as the commercial market for wearable, implantable, and connected glucose-sensing systems that measure interstitial or blood glucose repeatedly across the day and transmit glucose data to a reader, smartphone, insulin pump, or cloud platform. The market includes sensors, transmitters, receivers, mobile apps, algorithm software, data-sharing tools, and integrated CGM systems used for diabetes management and metabolic monitoring.
This analysis includes prescription CGMs, over-the-counter CGMs, real-time CGMs, intermittently scanned CGMs, implantable CGMs, and CGM components used with automated insulin delivery systems. It excludes traditional fingerstick blood glucose meters, laboratory glucose tests, HbA1c testing, insulin pumps without CGM integration, and generic wellness apps that do not use a glucose biosensor.
Key Takeaways
- Market Growth: The continuous glucose monitor market reached USD 13.80 billion in 2025 and is forecast to reach USD 47.74 billion by 2034, reflecting a 14.8% CAGR.
- Segment Dominance: Sensors held approximately 72.0% share in 2025, equal to USD 9.94 billion, because recurring sensor replacement drives the largest revenue pool.
- Segment Dominance: Type 1 diabetes and intensive insulin therapy represented approximately 52.0% share in 2025, equal to USD 7.18 billion, because these patients require frequent glucose decisions.
- Driver: Diabetes prevalence is the core demand driver, with IDF reporting that 11.1% of adults aged 20-79 lived with diabetes in 2025.
- Restraint: Product quality, alarm burden, skin irritation, pricing, and coverage restrictions restrain use; Abbott issued a correction involving roughly 3 million FreeStyle Libre 3 and Libre 3 Plus sensors in late 2025.
- Opportunity: Over-the-counter CGM is the largest new opportunity because Dexcom Stelo, Abbott Lingo, and Abbott Libre Rio expand access beyond intensive insulin users.
- Trend: Longer sensor wear is becoming a procurement differentiator, with Dexcom rolling out G7 15-Day and Senseonics commercializing Eversense 365.
- Regional: North America led the continuous glucose monitor market with approximately 47.0% share in 2025, equal to USD 6.49 billion.
Key Insights Summary
- Abbott reported USD 2.0 billion in fourth-quarter 2025 CGM sales, with 15.0% reported growth and 12.2% organic growth in Diabetes Care.
- Dexcom generated USD 4.662 billion in 2025 revenue, up 16% year over year, driven by demand for its CGM systems.
- Medtronic's diabetes unit generated USD 2.755 billion in fiscal 2025 revenue, up 10.7% as reported and 11.5% organically.
- Senseonics' investor materials referenced a USD 13.5 billion 2025 global CGM market and 38% utilization among eligible U.S. patients.
- Dexcom reported USD 1.19 billion in Q1 2026 revenue, up 15% year over year, and reaffirmed full-year 2026 revenue guidance of USD 5.16 billion to USD 5.25 billion.
- MiniMed raised USD 560 million in a March 2026 U.S. IPO, valuing the diabetes device business at USD 5.61 billion.
Competitive Landscape Overview
The continuous glucose monitor market is highly concentrated, with Abbott Laboratories and Dexcom controlling the largest revenue pools. Senseonics' November 2025 investor presentation referenced 2024 CGM revenue shares of 56.2% for Abbott, 34.9% for Dexcom, 8.7% for Medtronic, and less than 1% for Senseonics.
Competition is based on sensor accuracy, wear duration, cost per day, phone compatibility, reimbursement, automated insulin delivery integration, and consumer branding. Abbott competes on scale and lower-cost Libre access, Dexcom competes on premium real-time CGM and connectivity, Medtronic competes through pump-CGM integration, and Senseonics competes through implantable 365-day duration.
Competitive Landscape Matrix
| Company Name | Headquarters | Market Position | Key Product/Solution | Geographic Strength | Recent Strategic Move |
| Abbott Laboratories | United States | Leader | FreeStyle Libre, Lingo, Libre Rio | Global | Reported USD 2.0 billion Q4 2025 CGM sales. |
| Dexcom, Inc. | United States | Leader | Dexcom G6, G7, G7 15-Day, Stelo | North America, Europe | Reaffirmed 2026 revenue guidance after Q1 2026 revenue reached USD 1.19 billion. |
| MiniMed / Medtronic Diabetes | United States | Leader | Guardian CGM, MiniMed 780G system | United States, Europe | Raised USD 560 million in March 2026 IPO. |
| Senseonics Holdings, Inc. | United States | Challenger | Eversense 365 | United States, Europe | Priced USD 80 million public offering in May 2026. |
| Roche Diabetes Care | Switzerland | Challenger | Accu-Chek ecosystem | Europe, Asia | Competes through diabetes management devices and digital services. |
| Ascensia Diabetes Care | Switzerland | Challenger | Eversense commercialization partner | United States, Europe | Supports Senseonics' implantable CGM commercialization. |
| Ypsomed | Switzerland | Niche Player | mylife Loop insulin delivery ecosystem | Europe | Competes through pump and diabetes technology integration. |
| Tandem Diabetes Care | United States | Niche Player | t:slim X2 and Mobi pump integration | United States | Benefits from CGM-linked automated insulin delivery demand. |
| Insulet Corporation | United States | Niche Player | Omnipod 5 CGM-integrated insulin delivery | United States, Europe | Competes through tubeless insulin delivery linked to CGM data. |
| Glucotrack, Inc. | United States | Emerging Player | Implantable blood glucose monitoring technology | United States | Planned FDA IDE submission activity for implantable glucose monitoring. |
By Component
The continuous glucose monitor market by component is led by sensors, which held approximately 72.0% share in 2025, equal to USD 9.94 billion. Sensors dominate because CGM economics are recurring: users replace sensors every 10, 14, 15, 180, or 365 days depending on the system. Abbott FreeStyle Libre, Dexcom G7, Medtronic Guardian, and Senseonics Eversense 365 all depend on sensor replacement or sensor-service cycles.
Transmitters and receivers held approximately 13.0% share in 2025, equal to USD 1.79 billion. This category is shrinking as smartphones replace standalone receivers and as sensor-transmitter integration improves. Dexcom and Abbott benefit from app-centered adoption, while Senseonics retains a transmitter layer because the implanted sensor communicates with an external smart transmitter.
Software and data services held approximately 15.0% share in 2025, equal to USD 2.07 billion. This segment includes glucose trend analytics, remote data sharing, clinician dashboards, automated insulin delivery algorithms, food logging, coaching, and metabolic health insights. Software share is expected to rise through 2034 because OTC CGM depends on consumer interpretation rather than insulin dosing alone.
By Product Type
The continuous glucose monitor market by product type is led by real-time CGM systems, which held approximately 61.0% share in 2025, equal to USD 8.42 billion. Real-time CGMs dominate because they support alerts, data sharing, pump integration, and automated insulin delivery. Dexcom G7, Medtronic Guardian, and Senseonics Eversense fit this use case where rapid glucose visibility can prevent hypoglycemia or hyperglycemia.
Intermittently scanned CGMs held approximately 31.0% share in 2025, equal to USD 4.28 billion. Abbott's FreeStyle Libre built this segment through lower-cost access, broad pharmacy distribution, and strong international reimbursement. Libre's model competes well where affordability and scale matter more than full premium connectivity.
Implantable CGMs held approximately 3.0% share in 2025, equal to USD 0.41 billion. Senseonics' Eversense 365 gives this segment a distinctive long-wear claim because the implanted sensor can last one year. Adoption remains smaller because implantation requires trained providers and a different user workflow.
OTC CGMs held approximately 5.0% share in 2025, equal to USD 0.69 billion. Dexcom Stelo, Abbott Lingo, and Abbott Libre Rio opened a new channel for non-insulin type 2 diabetes and metabolic health consumers. This segment should grow faster than prescription-only CGM because it reduces access friction.
By End-User
The continuous glucose monitor market by end-user is led by homecare and self-management users, which held approximately 66.0% share in 2025, equal to USD 9.11 billion. CGM adoption is strongest in daily diabetes management because users need glucose trends during meals, sleep, exercise, illness, and medication changes. Abbott and Dexcom benefit most because their systems are designed for frequent personal use.
Hospitals and diabetes clinics held approximately 17.0% share in 2025, equal to USD 2.35 billion. These settings prescribe CGM, train users, adjust therapy, and monitor high-risk patients. Medtronic, Dexcom, Abbott, Roche Diabetes Care, and Ascensia compete for clinician trust because prescriptions often start through endocrinologists and diabetes educators.
Retail pharmacy and direct-to-consumer channels held approximately 11.0% share in 2025, equal to USD 1.52 billion. OTC clearance changes this channel because users can buy selected systems without a prescription. Dexcom Stelo and Abbott Lingo are important because they create a consumer market around glucose insights.
Research, employer health, and wellness programs held approximately 6.0% share in 2025, equal to USD 0.83 billion. This segment includes metabolic health studies, corporate wellness, obesity care, nutrition platforms, and GLP-1 support programs. Growth depends on whether consumers continue paying out of pocket after initial curiosity.
By Patient Group
The continuous glucose monitor market by patient group is led by type 1 diabetes and intensive insulin therapy, which held approximately 52.0% share in 2025, equal to USD 7.18 billion. This group has the strongest clinical need because glucose changes quickly and insulin dosing errors can be dangerous. Dexcom, Abbott, and Medtronic compete aggressively here through accuracy, alerts, insurance coverage, and insulin pump integration.
Type 2 diabetes using insulin held approximately 28.0% share in 2025, equal to USD 3.86 billion. This group is expanding because payers and clinicians increasingly recognize CGM's value for insulin titration and hypoglycemia detection. Abbott's Libre franchise has strong positioning because cost and broad access matter in type 2 diabetes.
Type 2 diabetes not using insulin held approximately 12.0% share in 2025, equal to USD 1.66 billion. This segment is moving from underpenetrated to commercially attractive because Dexcom Stelo and Abbott Libre Rio specifically target non-insulin users. Evidence generation remains important because reimbursement is less consistent than for intensive insulin therapy.
Non-diabetic metabolic health users held approximately 8.0% share in 2025, equal to USD 1.10 billion. Abbott Lingo and consumer metabolic apps drive this segment, but retention depends on whether users translate glucose data into lasting behavior change. This is the highest-upside and highest-churn part of the market.
Regional Analysis
The continuous glucose monitor market in North America held approximately 47.0% share in 2025, equal to USD 6.49 billion. The United States drives most regional revenue because FDA clearances, private insurance, Medicare coverage, pharmacy access, and diabetes device adoption are stronger than in most markets. Dexcom, Abbott, Medtronic, Senseonics, Insulet, Tandem Diabetes Care, and MiniMed all have major U.S. operations.
Europe held approximately 27.0% share in 2025, equal to USD 3.73 billion. Germany, the United Kingdom, France, Italy, Spain, the Netherlands, and the Nordics lead demand because CGM reimbursement has expanded across many insulin-treated populations. Abbott's Libre franchise has deep European penetration, while Dexcom and Medtronic compete through premium CGM and pump integration.
Asia Pacific held approximately 20.0% share in 2025, equal to USD 2.76 billion. China, Japan, India, South Korea, Australia, and Singapore are the largest growth engines. The region benefits from diabetes prevalence, smartphone adoption, urban healthcare access, and local device manufacturing. Growth is faster than North America because baseline CGM penetration is lower.
Latin America held approximately 4.0% share in 2025, equal to USD 0.55 billion. Brazil, Mexico, Argentina, Chile, and Colombia are the leading markets. Access remains uneven because out-of-pocket cost and public reimbursement limit recurring sensor use. Abbott's lower-cost positioning gives it an advantage in price-sensitive markets.
Middle East & Africa held approximately 2.0% share in 2025, equal to USD 0.28 billion. Saudi Arabia, the United Arab Emirates, Israel, South Africa, and Qatar lead adoption because diabetes burden and private healthcare capacity are higher than regional averages. Demand is strongest among insulin-treated patients and premium self-pay users.
Country Analysis
The continuous glucose monitor market in the United States was valued at approximately USD 5.92 billion in 2025 and is forecast to grow at a 13.9% CAGR through 2034. The United States leads because FDA-cleared OTC CGMs, pharmacy distribution, Medicare coverage, automated insulin delivery, and endocrinology networks support adoption. Dexcom's April 2026 quarterly revenue update and MiniMed's March 2026 IPO show that U.S. CGM demand remains active.
Germany was valued at approximately USD 0.78 billion in 2025 and is forecast to grow at a 12.8% CAGR through 2034. Germany benefits from structured diabetes care, reimbursement discipline, endocrinology networks, and European medtech adoption. Abbott, Dexcom, Medtronic, Roche Diabetes Care, and Ypsomed compete through clinical evidence and integration with diabetes management workflows.
China was valued at approximately USD 0.82 billion in 2025 and is forecast to grow at a 17.9% CAGR through 2034. China's growth comes from diabetes prevalence, urban hospital capacity, smartphone use, and demand for lower-cost sensors. Regulatory approval, local manufacturing, and physician education will determine whether CGM becomes a mainstream type 2 diabetes tool.
Japan was valued at approximately USD 0.54 billion in 2025 and is forecast to grow at a 15.6% CAGR through 2034. Japan benefits from aging demographics, type 2 diabetes burden, advanced medtech adoption, and strong specialist care. CGM use should grow in insulin-treated patients, older adults at hypoglycemia risk, and integrated diabetes technology programs.
Continuous Glucose Monitor Market
Size, by Region, 2025-2034 (USD)
The Market will Grow
At the CAGR of:
14.8%
The Forecast Market
Size for 2034 in USD:
$USD 47.74 B
Get more details on this report -
Key Market Segments
By Component
- Sensors
- Transmitters
- Receivers
- Integrated Insulin Pump Systems
- Mobile Applications and Software
- Cloud-Based Data Management Platforms
- Accessories and Consumables
- Others
By Product Type
- Real-Time Continuous Glucose Monitoring (rtCGM)
- Intermittently Scanned Continuous Glucose Monitoring (isCGM)
- Implantable Continuous Glucose Monitoring Systems
- Wearable Continuous Glucose Monitoring Systems
- Disposable Continuous Glucose Monitoring Systems
- Reusable Continuous Glucose Monitoring Systems
- Others
By End-User
- Hospitals
- Home Healthcare Settings
- Diabetes Clinics
- Ambulatory Surgical Centers (ASCs)
- Specialty Endocrinology Clinics
- Academic and Research Institutes
- Others
By Patient Group
- Type 1 Diabetes Patients
- Type 2 Diabetes Patients
- Gestational Diabetes Patients
- Prediabetic Individuals
- Pediatric Patients
- Adult Patients
- Geriatric Patients
- Others
By Regional Coverage
- North America
- Latin America
- East Asia And Pacific
- Sea And South Asia
- Eastern Europe
- Western Europe
- Middle East & Africa
| Report Attribute | Details |
| Market size (2025) | USD 13.80 B |
| Forecast Revenue (2034) | USD 47.74 B |
| CAGR (2025-2034) | 14.8% |
| Historical data | 2021-2024 |
| Base Year For Estimation | 2025 |
| Forecast Period | 2026-2034 |
| Report coverage | Revenue Forecast, Competitive Landscape, Market Dynamics, Growth Factors, Trends and Recent Developments |
| Segments covered | By Component, (Sensors, Transmitters, Receivers, Integrated Insulin Pump Systems, Mobile Applications and Software, Cloud-Based Data Management Platforms, Accessories and Consumables, Others), By Product Type, (Real-Time Continuous Glucose Monitoring (rtCGM), Intermittently Scanned Continuous Glucose Monitoring (isCGM), Implantable Continuous Glucose Monitoring Systems, Wearable Continuous Glucose Monitoring Systems, Disposable Continuous Glucose Monitoring Systems, Reusable Continuous Glucose Monitoring Systems, Others), By End-User, (Hospitals, Home Healthcare Settings, Diabetes Clinics, Ambulatory Surgical Centers (ASCs), Specialty Endocrinology Clinics, Academic and Research Institutes, Others), By Patient Group, (Type 1 Diabetes Patients, Type 2 Diabetes Patients, Gestational Diabetes Patients, Prediabetic Individuals, Pediatric Patients, Adult Patients, Geriatric Patients, Others), |
| Research Methodology |
|
| Regional scope |
|
| Competitive Landscape | ABBOTT LABORATORIES, DEXCOM, INC., MINIMED, SENSEONICS HOLDINGS, INC., MEDTRONIC PLC, ASCENSIA DIABETES CARE, ROCHE DIABETES CARE, TANDEM DIABETES CARE, INSULET CORPORATION, YPSOMED, GLUCOTRACK, INC., LIFESCAN, PHC HOLDINGS CORPORATION, SINOFI BIOTECH, MICROTECH MEDICAL, MEDTRUM TECHNOLOGIES, Others |
| Customization Scope | Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. |
| Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF). |
Frequently Asked Questions
How big is the Continuous Glucose Monitor Market?
The Global Continuous Glucose Monitor Market was valued at USD 12.10 Billion in 2024 and USD 13.80 Billion in 2025, and is projected to reach USD 47.74 Billion by 2034, growing at a CAGR of 14.8% from 2026 to 2034. Market growth is driven by wearable glucose monitoring, diabetes management, and digital healthcare technologies.
Who are the major players in the Continuous Glucose Monitor Market?
ABBOTT LABORATORIES, DEXCOM, INC., MINIMED, SENSEONICS HOLDINGS, INC., MEDTRONIC PLC, ASCENSIA DIABETES CARE, ROCHE DIABETES CARE, TANDEM DIABETES CARE, INSULET CORPORATION, YPSOMED, GLUCOTRACK, INC., LIFESCAN, PHC HOLDINGS CORPORATION, SINOFI BIOTECH, MICROTECH MEDICAL, MEDTRUM TECHNOLOGIES, Others
Which segments covered the Continuous Glucose Monitor Market?
By Component, (Sensors, Transmitters, Receivers, Integrated Insulin Pump Systems, Mobile Applications and Software, Cloud-Based Data Management Platforms, Accessories and Consumables, Others), By Product Type, (Real-Time Continuous Glucose Monitoring (rtCGM), Intermittently Scanned Continuous Glucose Monitoring (isCGM), Implantable Continuous Glucose Monitoring Systems, Wearable Continuous Glucose Monitoring Systems, Disposable Continuous Glucose Monitoring Systems, Reusable Continuous Glucose Monitoring Systems, Others), By End-User, (Hospitals, Home Healthcare Settings, Diabetes Clinics, Ambulatory Surgical Centers (ASCs), Specialty Endocrinology Clinics, Academic and Research Institutes, Others), By Patient Group, (Type 1 Diabetes Patients, Type 2 Diabetes Patients, Gestational Diabetes Patients, Prediabetic Individuals, Pediatric Patients, Adult Patients, Geriatric Patients, Others),
How can this market research report help my business make strategic decisions?
Our market research reports provide actionable intelligence, including verified market size data, CAGR projections, competitive benchmarking, and segment-level opportunity analysis. These insights support strategic planning, investment decisions, product development, and market entry strategies for enterprises and startups alike.
How frequently is the data updated?
We continuously monitor industry developments and update our reports to reflect regulatory changes, technological advancements, and macroeconomic shifts. Updated editions ensure you receive the latest market intelligence.
Select Licence Type
Connect with our sales team
Continuous Glucose Monitor Market
Published Date : 02 Jul 2026 | Formats :Why IntelEvoResearch
100%
Customer
Satisfaction
24x7+
Availability - we are always
there when you need us
200+
Fortune 50 Companies trust
IntelEvoResearch
80%
of our reports are exclusive
and first in the industry
100%
more data
and analysis
1000+
reports published
till date